119 related articles for article (PubMed ID: 6994159)
1. Influence of pH on the prostacyclin (PGI2) mediated inhibition of platelet function.
Rao GH; Reddy KR; Hagert K; White JG
Prostaglandins Med; 1980 Apr; 4(4):263-73. PubMed ID: 6994159
[TBL] [Abstract][Full Text] [Related]
2. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.
Lombroso M; Nicosia S; Paoletti R; Whittle BJ; Moncada S; Vane JR
Prostaglandins; 1984 Feb; 27(2):321-33. PubMed ID: 6326201
[TBL] [Abstract][Full Text] [Related]
3. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
4. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.
Ehrman ML; Jaffe EA
Prostaglandins; 1980 Dec; 20(6):1103-16. PubMed ID: 7010448
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of PGI2 production by isolated perfused rat lungs with platelet aggregation test.
Hartiala J; Toivonen H; Uotila P
Prostaglandins; 1980 Jul; 20(1):127-34. PubMed ID: 6996035
[TBL] [Abstract][Full Text] [Related]
6. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
[TBL] [Abstract][Full Text] [Related]
7. Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro.
Saniabadi AR; Lowe GD; Belch JJ; Barbenel JC; Forbes CD
Haemostasis; 1984; 14(6):487-94. PubMed ID: 6442909
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet aggregation and elevation of cyclic-AMP levels in platelets by 13,14-dehydro PGI2 methyl ester.
Malmsten C; Claesson HE; Fried J
Prostaglandins Med; 1980 Jun; 4(6):453-63. PubMed ID: 6251494
[TBL] [Abstract][Full Text] [Related]
9. Heparin neutralization of PGI2: effects upon platelets.
Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
[TBL] [Abstract][Full Text] [Related]
10. Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation.
Parise LV; Venton DL; Le Breton GC
Thromb Res; 1982 Dec; 28(6):721-30. PubMed ID: 6301090
[TBL] [Abstract][Full Text] [Related]
11. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers.
Reele SB; Miller OV; Spillers C; Gorman RR
Prostaglandins; 1983 Aug; 26(2):287-302. PubMed ID: 6316420
[TBL] [Abstract][Full Text] [Related]
12. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
Jaschonek K; Faul C; Daiss W; Weisenberger H
Prostaglandins Leukot Med; 1986 Oct; 24(2-3):199-206. PubMed ID: 2432618
[TBL] [Abstract][Full Text] [Related]
13. The influence of epinephrine on prostacyclin (PGI2) induced dissociation of ADP aggregated plateletes.
Rao GH; Reddy KR; White JG
Prostaglandins Med; 1980 Jun; 4(6):385-97. PubMed ID: 6251492
[TBL] [Abstract][Full Text] [Related]
14. Effect of nonesterified fatty acids on the stability of prostacyclin activity.
Mikhailidis DP; Mikhailidis AM; Barradas MA; Dandona P
Metabolism; 1983 Jul; 32(7):717-21. PubMed ID: 6345992
[TBL] [Abstract][Full Text] [Related]
15. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function.
Levin RI; Weksler BB; Jaffe EA
Circulation; 1982 Dec; 66(6):1299-307. PubMed ID: 6291803
[TBL] [Abstract][Full Text] [Related]
16. Effect of dipyridamole on prostaglandin generation by human platelets and vessel walls.
Mehta J; Mehta P; Hay D
Prostaglandins; 1982 Dec; 24(6):751-61. PubMed ID: 6820166
[TBL] [Abstract][Full Text] [Related]
17. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.
Wong PY; Lee WH; Chao PH; Reiss RF; McGiff JC
J Biol Chem; 1980 Oct; 255(19):9021-4. PubMed ID: 6997309
[TBL] [Abstract][Full Text] [Related]
19. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
Wong PY; McGiff JC; Sun FF; Lee WH
Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of anti-aggregating activity of PGI2 by 7-ethoxycarbonyl-6,8-dimethyl-4-hydroxymethyl-1(2H)-phthalazinone (EG-626) in rabbit platelets in vitro.
Tanaka K; Harada Y; Iwata M; Katori M
Prostaglandins; 1980 Aug; 20(2):255-68. PubMed ID: 6997930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
